Key Sessions
Laura Walker, PhD
Human Antibody Responses to Infection and Vaccination
Moderna
Shannon Turley, PhD
Evolution of Stromal Niches in Inflammation, Cancer and Immunotherapy
Genentech
Kole Roybal, PhD
Towards the Development of Synthetic Immunity to Cancer
UCSF School of Medicine
Bassil Dahiyat, PhD
Xencor’s 20 Year Journey in Antibody Therapeutic Development
Xencor
keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
MAIN CONFERENCE DEC. 14 - MT (Mexican Pacific Time, GMT-07:00)
keyboard_arrow_leftSearch & Filter
search
Streams
Formats
MAIN CONFERENCE DEC. 14 - MT (Mexican Pacific Time, GMT-07:00)
search
Streams
Formats
7:00am - 8:00am
Registration and Breakfast
Showing 1 of 1 Streams
Keynote Presentations
8:00am - 8:05am
Co-Chairs' Welcome and Opening Remarks
- Janine Schuurman, Ph.D. - Biotech Consultant, Lust for Life Science
- Sally Ward, PhD - Professor and Director, University of Southampton
8:05am - 8:45am
Human Antibody Responses to Infection and Vaccination
- Laura Walker, PhD - Head of Infectious Disease Biotherapeutics Discovery & Engineering, Moderna
8:45am - 8:50am
Keynote Questions
8:50am - 9:30am
Evolution of Stromal Niches in Inflammation, Cancer and Immunotherapy
- Shannon Turley, PhD - Vice President and Therapeutic Area Head, Immunology and Regenerative Medicine, Genentech
9:30am - 9:35am
Keynote Questions
9:35am - 10:05am
Networking Refreshment Break
10:05am - 10:45am
Towards the Development of Synthetic Immunity to Cancer
- Kole Roybal, PhD - Associate Professor, Microbiology & Immunology, UCSF School of Medicine
10:45am - 10:50am
Keynote Questions
10:50am - 11:30am
Xencor’s 20 Year Journey in Antibody Therapeutic Development
- Bassil Dahiyat, PhD - President and CEO, Xencor
11:30am - 11:35am
Keynote Questions
11:35am - 12:10pm
Jim Huston Science Talent Award Winner Presentation: IgE Class Antibody Therapeutics for Cancer
- Heather Bax - Postdoctoral Research Fellow, King's College London
- Janine Schuurman, Ph.D. - Biotech Consultant, Lust for Life Science
- Sally Ward, PhD - Professor and Director, University of Southampton
12:10pm - 12:15pm
Transition to Scientific Luncheon Briefings
Showing 6 of 6 Streams
Scientific Luncheon Briefing 1
Scientific Luncheon Briefing 2
Scientific Luncheon Briefing 3
Scientific Luncheon Briefing 4
Scientific Luncheon Briefing 5
Scientific Luncheon Briefing 6
12:15pm - 1:15pm
Transgenic Chickens Producing Human Heavy Chain-only Antibodies Demonstrate Robust Immune Repertoires and High-affinity Binding
- Christine Vuong - Senior Research Scientist, OmniAb
12:15pm - 1:15pm
Writing the Future of Biologics with an Integrated Offering of Immunization, Libraries, and Machine Learning
- Aaron Sato, PhD - Chief Scientific Officer, Twist Bioscience
12:15pm - 1:15pm
Robust Production of Antibody Fragments and Their Therapeutic Applications/Applying High Throughput Novel Pairing Technology to Discover Diverse Native Antibodies from Bulk B Cells
- Heng Tai Liew, PhD - Senior Scientist, GenScript
- Gladys Keitany, PhD - Associate Director, BCR/Antibody Discovery, Adaptive Biotechnologies
12:15pm - 1:15pm
Ab Discovery Platforms with Precision Targeting Down to a Single AA
- Kalyani Mondal, PhD - Associate Director, Biosensors, Charles River Laboratories
- Joshua Royal, PhD - Principal Scientist, KBio
12:15pm - 1:15pm
Multiparametric Therapeutic Antibody Optimization using High Quality Assays and Machine Learning
- Jennifer Codding-Bui, PhD - Senior Scientist, Protein Engineering, ATUM
12:15pm - 1:15pm
Celebrating Diversity: AlivaMab® Discovery and Engineering Platforms for Novel Biologic Therapeutics
- Jane Seagal, PhD - Vice President, Antibody Discovery, AlivaMab Biologics
- Larry Green, PhD - CEO, Ablexis
- Ankita Srivastava, PhD - VP, Antibody Engineering and Protein Sciences, AlivaMab Biologics
Showing 5 of 5 Streams
Scientific Briefing 1
Scientific Briefing 2
Scientific Briefing 3
Scientific Briefing 4
Scientific Briefing 5
1:15pm - 1:45pm
AI/ML-ab™: Converting in silico Designed Antibodies into Reality
- Richard Buick, PhD - Chief Scientific Officer, Fusion Antibodies plc
1:15pm - 1:45pm
Tackling Tough Targets in Antibody Discovery by Leveraging a Diverse Suite of In Vivo Discovery Platforms
- Thomas Vincent - Senior Director of Antibody Technology, Alloy Therapeutics
1:15pm - 1:45pm
Valita Aggregation Pure, A High-Throughput, Protein Aggregation Screening Tool for Bioprocessing
- Chip Slaybaugh, PhD - Technical Sales Specialist, Beckman Coulter LS
1:15pm - 1:45pm
Accelerating Chimeric Antigen Receptor Discovery: From Targets to Leads with ProCAR™ Platform
- Yu Liang, PhD - Vice President, Research & Development, GenScript ProBio USA Inc.
1:15pm - 1:45pm
Advances in Lead Discovery with High-throughput Sequencing Data and In-silico Models
- Nestor Vazquez Bernat - Application Science Team Lead, ENPICOM
Showing 5 of 5 Streams
Scientific Briefing 1
Scientific Briefing 2
Scientific Briefing 3
Scientific Briefing 4
Scientific Briefing 5
1:45pm - 2:15pm
Therapeutic Antibody Engineering for Highly Stable Formulations by Using a Machine Learning-guided Protein Engineering Technique, aiProtein®
- Norio Hamamatsu, PhD - Senior Director, RevolKa Ltd.
1:45pm - 2:15pm
Software at Every Stage: Achieving Antibody Discovery at Scale
- Scott Rehlander - Vice President, Products and Innovation, StackWave
1:45pm - 2:15pm
The Fastest Route to Mono- and Bi-Specific Therapeutic Lead Candidates using the SpyTag Technology
- Katharina Reefschläger, PhD - Technical Sales Specialist, Custom Antibodies, Bio-Rad AbD Serotec GmbH
1:45pm - 2:15pm
How to Use Display Technologies to Discover Therapeutic Proteins Against Challenging Targets
- George Wang, PhD - Vice President of Antibody Discovery, WuXi Biologics
1:45pm - 2:15pm
Tools for Accelerated PK and ADA Screening of Therapeutic Antibody Candidates
- Jasmine Singh - Field Application Scientist-West Coast, Gyros Protein Technologies
Showing 2 of 2 Streams
Track 1: Novel Bispecifics, Multi-specifics and Therapeutic Combinations
Track 2: Antibody Discovery, Selection and Engineering
2:25pm - 2:30pm
Chairman’s Remarks
- Janine Schuurman, Ph.D. - Biotech Consultant, Lust for Life Science
- James Ernst, Ph.D. - Senior Director, Head of Development Sciences, Xencor
2:30pm - 3:00pm
Identifying Optimal Targets and Target Pairs for Multi-specific Targeted Therapies
- David Kugler, Ph.D. - Vice President of Immunology, Cartography Biosciences
3:00pm - 3:30pm
Design Meets Biology – Engineering Immune Engagers with Potentially Improved Therapeutic Index
- John Schardt, Ph.D. - Senior Scientist, AstraZeneca
3:30pm - 4:00pm
Multabodies: Exploiting Avidity and Multi-specificity to Achieve Ultra-potent Biologics
- Joanne Hulme, Ph.D. - Chief Scientific Officer, Radiant Biotherapeutics
2:25pm - 2:30pm
Co-Chairs’ Remarks
- Andrew Bradbury, MD, PhD - Chief Scientific Officer, Specifica
2:30pm - 3:00pm
Affinity/Efficacy Relationships for Different Antibody Modalities
- Karl Dane Wittrup, Ph.D. - C.P. Dubbs Professor in Chemical Engineering and Biological Engineering, Massachusetts Institute of Technology
3:00pm - 3:30pm
Using Yeast Two Hybrid for Antibody Selection: Applications to Alzheimer's Disease
- Antonino Cattaneo - Professor of Neurobiology, Scuola Normale Superiore
3:30pm - 4:00pm
Antibody Reactome Profiling via Molecular Display and Sequencing of Antigen Libraries
- H. Benjamin Larman, Ph.D. - Associate Professor, Immunopathology, Johns Hopkins School of Medicine
4:00pm - 4:45pm
Networking Refreshment Break and Opening of Exhibit and Poster Hall
Showing 2 of 2 Streams
Track 1: Novel Bispecifics, Multi-specifics and Therapeutic Combinations
Track 2: Antibody Discovery, Selection and Engineering
4:45pm - 5:15pm
A METxMET Bispecific Antibody and ADC for Cancer Therapy
- John DaSilva - Scientist, Regeneron Pharmaceuticals
5:15pm - 5:45pm
A Novel Antibody Targeting the HLA-DQ2.5/Gluten Peptide Complex with Broad Cross-reactivity and Selectivity
- Akihiko Mizoroki - Senior Principal Scientist, Chugai Pharmabody Research
5:45pm - 6:15pm
Dual-cell Bidirectional (DcB) Antibodies for Targeting Multiple Inhibitory Pathways for Controlling Inflammation
- Jyothsna Visweswaraiah, PhD - Director, Biotherapeutics Drug Creation, Seismic Therapeutic
4:45pm - 5:15pm
Novel Strategies for Antibody Selection: pH Sensitive Antibodies
- Andrew Bradbury, MD, PhD - Chief Scientific Officer, Specifica
5:15pm - 5:45pm
Sequence Enrichment Profiles Enable tTarget-agnostic Antibody Generation for a Broad Range of Antigens
- Jenny Mattsson - Principal Scientist, BioInvent International AB
5:45pm - 6:15pm
Development of a Versatile, Synthetic, Heavy Chain-only Antibody Platform in a Yeast-based Therapeutic Discovery Platform
- Bradley Lunde, Ph.D. - Group Leader, Antibody Engineering, Adimab
6:15pm - 7:45pm
Opening Night Networking Reception, Exhibits and Poster Viewing
Get the Latest Event Updates
Sign up to get the latest event updates and information.
Filter
Streams
Formats